The Novavax vaccine candidate is currently in late-stage clinical studies
- The company aims to deliver initial doses to Australia by mid-2021
- Australia will have the option to purchase up to an additional 10 million doses.
Most Popular
Sponsored
SpaceX eyes $75B IPO at $1.75T valuation for orbital data centers, a bold bet on future tech.
Navan director buys $1.2M shares, nearly doubling his stake. Stock's P/S near yearly low, but losses mount.
AI stocks like NVDA surge, but traders eye bubble burst risks. Valuations are sky-high.
EverCommerce President sold 20K shares ($229K), maintaining 2.3M+ shares. High P/E (115) suggests selling now.
TALO insider sold $38.5M shares, 5.31% of holdings. Still holds 41.2M shares. 1-yr return: 123.9%
Middle East threats loom for AMZN, MSFT, NVDA, but their vast global scale limits impact.
S&P 500 rebounds 2.9% on Iran de-escalation hopes; earnings growth stays strong.
Sponsored
Must Read